Gideon Capital Advisors Inc. decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 37.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,070 shares of the pharmaceutical company’s stock after selling 1,216 shares during the quarter. Gideon Capital Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $352,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VRTX. Mount Yale Investment Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $101,000. Kaizen Advisory LLC boosted its holdings in shares of Vertex Pharmaceuticals by 147.3% during the 2nd quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after acquiring an additional 358 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Vertex Pharmaceuticals by 3,126.1% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock valued at $126,000 after acquiring an additional 719 shares in the last quarter. Signaturefd LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $131,000. Finally, Point72 Asia Hong Kong Ltd acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $161,000. 92.83% of the stock is currently owned by institutional investors.

Several brokerages have commented on VRTX. Jefferies Financial Group lifted their target price on Vertex Pharmaceuticals to $210.00 and gave the stock a “buy” rating in a report on Monday, July 16th. BMO Capital Markets lifted their target price on Vertex Pharmaceuticals to $204.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Royal Bank of Canada reaffirmed a “buy” rating and set a $203.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, July 26th. Stifel Nicolaus lifted their target price on Vertex Pharmaceuticals from $182.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, August 7th. Finally, Citigroup lifted their target price on Vertex Pharmaceuticals from $203.00 to $206.00 and gave the stock a “buy” rating in a report on Monday, July 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-four have given a buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $193.75.

VRTX stock opened at $176.08 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $136.50 and a 1-year high of $183.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.67 and a quick ratio of 3.55. The stock has a market capitalization of $44.68 billion, a PE ratio of 220.10, a price-to-earnings-growth ratio of 1.78 and a beta of 1.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 25th. The pharmaceutical company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.40 by $0.54. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. The firm had revenue of $752.20 million during the quarter, compared to analyst estimates of $680.86 million. During the same period last year, the company posted $0.39 EPS. The business’s quarterly revenue was up 38.2% on a year-over-year basis. analysts expect that Vertex Pharmaceuticals Incorporated will post 2.48 earnings per share for the current year.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 860 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, July 12th. The stock was sold at an average price of $175.02, for a total transaction of $150,517.20. Following the completion of the transaction, the senior vice president now owns 16,947 shares in the company, valued at approximately $2,966,063.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul M. Silva sold 2,957 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, June 29th. The shares were sold at an average price of $166.52, for a total value of $492,399.64. Following the transaction, the senior vice president now owns 16,946 shares of the company’s stock, valued at approximately $2,821,847.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 204,540 shares of company stock valued at $33,362,508. Corporate insiders own 0.75% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Read More: What does RSI mean?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.